This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 May 29;123(22):3368-70.

doi: 10.1182/blood-2014-04-563890.

CLL and NHL: the end of chemotherapy?

Bruce D Cheson¹

Affiliations

PMID: 24876522
DOI: 10.1182/blood-2014-04-563890

Comment

CLL and NHL: the end of chemotherapy?

Bruce D Cheson. Blood. 2014.

. 2014 May 29;123(22):3368-70.

doi: 10.1182/blood-2014-04-563890.

Author

Bruce D Cheson¹

Affiliation

¹ GEORGETOWN UNIVERSITY HOSPITAL.

PMID: 24876522
DOI: 10.1182/blood-2014-04-563890

No abstract available

PubMed Disclaimer

Comment on

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND. Kahl BS, et al. Blood. 2014 May 29;123(22):3398-405. doi: 10.1182/blood-2013-11-537555. Epub 2014 Mar 10. Blood. 2014. PMID: 24615778 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Other Literature Sources
- scite Smart Citations